On Friday 3rd of February, the Therapeutic Goods Administration (TGA) announced that from July 1st this year, medicines containing the psychedelic substances psilocybin and MDMA can be prescribed by specifically authorised psychiatrists for the treatment of certain mental health conditions.
A Monash University expert is available to discuss this topic.
Professor Langmead is available on the afternoon of Sunday 5th February. He also has availability during the week.
Professor Chris Langmead, Deputy Director of the Neuromedicines Discovery Centre, Monash Institute of Pharmaceutical Sciences
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).